Fig1.jpg (Fig1)
The text appears to be a report on the results of a study comparing the effectiveness of two drugs, Atenolol and Losartan, in reducing the risk of a primary endpoint in a group of patients. The study lasted for 66 months and showed an adjusted risk reduction of 13%. The text also contains a graph with time intervals, but the data is not enough to properly interpret it.*